Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain
Open Access
- 18 June 2024
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 20 (1) , 2365804
Abstract
Respiratory syncytial virus (RSV) is the main cause of low respiratory tract infections in infants under one year of age. In the 2023/2024 season, the monoclonal antibody nirsevimab was available to protect children from RSV, and Spain has become one of the first countries worldwide to implement this strategy. It is essential to evaluate the results of this first campaign and different characteristics of the immunized population in order to plan next campaigns, especially for countries that are going to include this immunization. Our coverage was high (91.5% for those born during the season and 88.3% globally). For those born during the season, only 4.9% preferred not to immunize at the maternity hospital, which meant an average delay of 27.45 days. We observed a lower coverage in the population of immigrant origin. There was a rapid pace of immunization, since for those born before the beginning of the campaign the mean to be immunized was 15.63 days, without differences between healthy and at-risk children. This allows immunization before the RSV season (90% of the catch-up children had been immunized on November 3). The average age at which all the immunized children have received nirsevimab was lower in healthy children compared to those with risk conditions (49.65 versus 232.85 days). For those born during the campaign, the average age was also lower in healthy children (3.14 versus 14.58 days). In conclusion, we consider that the implementation of the immunization strategy with nirsevimab in the Region of Murcia, Spain, has been a success.Keywords
Funding Information
- Sanofi Spain
This publication has 18 references indexed in Scilit:
- Nirsevimab for Prevention of Hospitalizations Due to RSV in InfantsNew England Journal of Medicine, 2023
- Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 yearsThe Journal of Infectious Diseases, 2023
- Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodiesExpert Review of Vaccines, 2022
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Expert consensus on palivizumab use for respiratory syncytial virus in developed countriesPaediatric Respiratory Reviews, 2020
- Comparison of early childhood vaccination coverage and timeliness between children born to Italian women and those born to foreign women residing in Italy: A multi-centre retrospective cohort studyVaccine, 2019
- Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm InfantsThe Pediatric Infectious Disease Journal, 2018
- Recommendation for Use of Immunization Information Systems to Increase Vaccination RatesJournal of Public Health Management & Practice, 2015
- Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three‐year prospective studyActa Paediatrica, 2010
- Vaccination coverage against measles in German-born and foreign-born children and identification of unvaccinated subgroups in GermanyVaccine, 2009